Search clinical trials for: EBI-005

Total 5794 results

Eleven Biotherapeutics

Completed

Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects (EBI-005-1)

Dry Eye

United States
DermBiont, Inc.

Suspended

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

Onychomycosis

United States
Eleven Biotherapeutics

Completed

A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis (EBI-005-AC-2)

Allergic Conjunctivitis (AC)

United States
University of Manitoba
Canadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS); The Canadian Collaborative for Childhood Cannabinoid Therapeutics

Not yet recruiting

CANnabinoids in Pediatric ONCology (CAN-PONC)

Cancer | Childhood Cancer
University of Pennsylvania

Terminated

Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection

Recurrent Clostridium Difficile Infection

United States
DermBiont, Inc.

Active, not recruiting

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

Tinea Pedis

United States
Revibe Technologies

Completed

Assessing a Wearable Digital Therapy for Youth With ADHD

ADHD

United States
Eleven Biotherapeutics

Unknown

Study of EBI-005 in Dry Eye Disease (DED) (EBI-005)

Dry Eye

United States
Eleven Biotherapeutics

Completed

A Multi-Center Study Subjects With Dry Eye Syndrome (EBI)

Dry Eye Syndrome

United States
EyeGene Inc.
Novotech (Australia) Pty Limited

Completed

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers

Prevention of Herpes Zoster (HZ)

Australia
University of Pennsylvania

Terminated

Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)

Severe Clostridium Difficile Infection | Severe-Complicated/Fulminant Clostridium Difficile Infection

United States
Buzzard Pharmaceuticals
Baylor Research Institute

Recruiting

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

Solid Tumor, Adult

United States
Eleven Biotherapeutics

Completed

Phase 3 Study of EBI-005 in Dry Eye Disease (EBI-005)

Dry Eye Disease (DED)

United States
EGEN, Inc.

Terminated

Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

Ovarian Neoplasms

United States
Eleven Biotherapeutics

Completed

A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)

Allergic Conjunctivitis

Canada
eTheRNA immunotherapies

Terminated

Safety of Intranodal ECI-006 in Melanoma Patients

Melanoma

Belgium, Spain
EGEN, Inc.

Completed

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

Ovarian Neoplasms

United States
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Subjects With Asthma

Asthma
Johnson & Johnson Consumer Inc. (J&JCI)

Completed

A Controlled Clinical Study of 2 Different Moisturizers for the Relief of Dry Skin

Skin Care | Skin | Skin Cream

United States
DermBiont, Inc.
Derm Research, PLLC; Northsoundderm; ClearDermatologyandAestheticsCenter

Terminated

Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel

Atopic Dermatitis

United States
PMG Pharm Co., Ltd

Completed

Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs

Arthritis

Korea, Republic of
Azura Ophthalmics
ORA, Inc.

Not yet recruiting

A Phase 3 Study to Evaluate AZR-MD-001 in Patients With Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Dry Eye Disease

United States
ChemRar Research and Development Institute, LLC

Not yet recruiting

A Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder

Anxiety Disorder Generalized
Hillhurst Biopharmaceuticals, Inc.
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

Anemia, Sickle Cell

United States
Hillhurst Biopharmaceuticals, Inc.
National Heart, Lung, and Blood Institute (NHLBI)

Not yet recruiting

A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

Anemia, Sickle Cell

United States
Kukje Pharma

Completed

[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001

Dry Eye Syndromes

Korea, Republic of
Creabilis SA

Completed

Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

United States, United Kingdom
Oncology Institute of Vojvodina

Recruiting

Ultra-hypofractionated for Whole Breast Irradiation (WBI) Compared to Partial Breast Irradiation (PBI)

Breast Cancer Female

Serbia
Seelos Therapeutics, Inc.

Withdrawn

SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease ([STRIVE-AD])

Alzheimer's Disease

Australia
Hoth Therapeutics, Inc.
Worldwide Clinical Trials

Recruiting

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors (CLEER)

Acneiform Eruption Due to Chemical | Xerosis Cutis | Paronychia

United States
Longbio Pharma

Recruiting

A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants

Paroxysmal Nocturnal Hemoglobinuria (PNH)

China
VBI Vaccines Inc.
Clinical Trial Data Services, LLC

Completed

Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults

Cytomegalovirus Infections

Canada
Pfizer

Completed

A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.

Smoking | Vaccines

Canada
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Healthy Subjects

Influenza A H3N2

United Kingdom
California State University, Long Beach

Completed

Active Moms Project: Physical Activity Intervention for Low-Income Mothers

Physical Inactivity
Ontario Clinical Oncology Group (OCOG)

Recruiting

A Randomized Trial of Five Fraction Partial Breast Irradiation

Breast Neoplasm Female | Radiotherapy | Cosmetic Outcome

Canada
Pfizer

Terminated

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

Alzheimer Disease

United States, Spain, France, Japan, New Zealand, Belgium, Portugal, Netherlands, Argentina, United Kingdom, Australia, Slovakia, Poland, Chile, Finland, Italy, South Africa, Sweden, Switzerland
Elicio Therapeutics

Recruiting

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (AMPLIFY-7P)

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | KRAS G12D | KRAS G12R | NRAS G12D | NRAS G12R | KRAS G12V | KRAS G12C | KRAS G12A | KRAS G12S | KRAS G13D | NRAS G12V | NRAS G12C | NRAS G12S

United States
Memorial Sloan Kettering Cancer Center
BMS Foundation

Recruiting

Study of Peripheral Arterial Disease (PAD) in People With Cancer Who Will Be Having Surgery

Peripheral Arterial Disease (PAD) in Cancer Patients

United States
Elicio Therapeutics

Active, not recruiting

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)

Colorectal Cancer | Ovarian Cancer | Cholangiocarcinoma | Bile Duct Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Minimal Residual Disease | Gallbladder Carcinoma | KRAS G12D | KRAS G12R | NRAS G12D | NRAS G12R

United States
Celgene

Withdrawn

A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Solid Tumor

United States
Skye Bioscience, Inc.

Completed

Phase 2, Placebo-Controlled, Study Assessing the Safety and Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Patients With Elevated Eye Pressure

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Bonti, Inc.

Completed

Study of EB-001 in Facial Scar Reduction

Mohs Surgery

United States
BioInvent International AB

Completed

A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

Multiple Myeloma

Denmark, Belgium, United States, Sweden
Seattle Children's Hospital
Aadi Bioscience, Inc.

Completed

ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)

Epilepsy Intractable

United States
BioInvent International AB

Terminated

A Phase II Study of BI-505 in Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

Sweden
Aadi Bioscience, Inc.

Withdrawn

ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome

Leigh Syndrome
Celgene

Completed

Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

Alzheimer's Disease

United States, Germany, Canada, Austria
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

Alzheimer's Disease

United States

Search clinical trials for: EBI-005

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations